

Patient Safety Information Card



Concentrate for solution for infusion, tagraxofusp 1 mg/mL

Adverse event reporting

Reporting about adverse events to the Israeli Ministry of Health can be done via the portal for Reporting Side Effects, found on the home page of the Israeli Ministry of Health website www.health.gov.il, or by entering the link: <https://sideeffects.health.gov.il/>

How to use this card

- Fill out the back of the card with your name, the date you started receiving ELZONRIS, and your prescribing Doctor's name and phone number
- Immediately put the card in your wallet or purse
- Show this card to any healthcare provider if you go to Emergency Department or if you see any other healthcare provider

- Ask your cancer treatment team for another card if your card is lost or damaged
- Keep this card in your wallet or purse until your treatment team tells you that you don't need it anymore

ELZONRIS treatment may cause Capillary Leak Syndrome (CLS). Seek urgent medical attention if you notice any of the following signs and symptoms:

- Sudden weight gain
- Swelling or puffiness
- Dizziness
- Difficulty breathing
- A general feeling of tiredness

Patient Name: _____

ELZONRIS Start Date: _____

Prescribing Doctor: _____

Doctor's phone number: _____

Contact your Doctor immediately for more information.

This card was checked and approved by Israeli Ministry of Health in January 2024.